IV Transfus. Sci. Vol. 18, No. 4

inhibiting reocclusion without inducing a systemic effect.

5626884

T R E A T M E N T O F S I C K L E C E L L

D I S E A S E

Lockett Cu~is G New Odeans, LA, UNITED STATES

A maintenance regimen with controlled intake of particular vitamin, mineral, and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations include vitamin A, vitamin B-l, vitamin B-2, vitamin B-6, vitamin B-12, vitamin C, vitamin D, vitamin E, niacinamide, para-aminobenzoic acid (PABA), pantothenic acid, choline bitartrate, inositol, rutin, citrus bioflavonoid complex, betaine hydrochloride, hesperidin complex, folic acid, biotin, calcium, iron, magnesium, zinc, potassium, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier, provided at or just below critical saturation levels, determined for each individual by carefully monitoring tolerance on titration. The daily dose may exceed that necessary as dietary or nutritional supplements, and trigger an increase in the production of viable hemoglobin, and alters the overall blood profile. Platelet concentration is increased up to twice that of seen in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is achieved by providing sufficient stores of precursors that stimulate low level manufacture without substantial feedback control by the upper central nervous system.

5627036

USE O F AN A N T I C O A G U L A N T AS A D I A G N O S T I C A G E N T

Reutelingsperger Christiaan Maastricht, NETHERLANDS assigned to Boehringer lngelheim International GmbH

Detectably labelled annexines and compositions thereof are disclosed. Also disclosed are methods for diagnosing a disruption or activation of the hemostatic system or a prothrombotic state in an individual suspected of having a hemostatic disorder, by contacting the blood of said individual with an annexine, and detecting whether an annexine-platelet complex is formed.

5628727

E X T R A C O R P O R E A L V I R I O N C I D A L A P P A R A T U S

Hakky Said I; Hakki A-Hamid; Hudson Perry B Largo, FL, UNITED STATES

An extracorporeal radiation-therapy apparatus for use in treating the blood of a donor for diseased cells or organisms. The apparatus separates the blood by a density gradient device and treats the different blood fractions with drugs and/or high energy radiation.

5629294

C O M P O S I T I O N S AND M E T H O D S

F O R P R E V E N T I N G A D H E S I O N

F O R M A T I O N

diZerega Gere S; Rodgers Kathleen E Pasadena, CA, UNITED STATES assigned to University of Southern California

Compositions and methods for prevention of adhesion formation, whereby an effective amount of one or more adhesion preventing RGD-containing peptides is administered for a period of time sufficient to permit tissue repair. The RGD-containing peptide is further characterized in that it inhibits platelet aggregation and does not induce inflammation or trauma at the site of administration. The RGD-containing peptide is preferably administered in conjunction with a delivery vehicle (e.g., microcapsules, microspheres, liposomes, viscous instillates and absorbable mechanical barriers) useful for maintaining local concentrations of the peptide at an effective level.

5629321

B I C Y C L I C C O M P O U N D A N D

P L A T E L E T A G G R E G A T I O N I N H I B I T O R C O N T A I N I N G T H E

S A M E

Okumura Kunio; Yokoyama Isao; Shimazaki Toshiyuki; Miyamoto Michihiko; Yamashita Hiroyuki; Kibayashi Kcnji; Yutaka Takanori; Yazawa Kouhci Chiba ken, JAPAN assigned to Mitsui Toatsu Chemicals Inc